Research that FDA is requesting on consumer understanding of umbrella branding could shrink or stretch the gulf between the agency and OTC drug firms over the potential risks of using the same proprietary name for products with different ingredients and indications.
The Center for Drug Evaluation and Research’s request for proposals posted July 16 suggests FDA continues to consider whether to limit umbrella branding more narrowly than current practices,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?